by Impulse Dynamics | May 10, 2018 | Press Releases
Orangeburg, New York, May 10, 2018 – Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure. The study results were presented by Prof. William Abraham, MD, Professor of...
by Impulse Dynamics | Dec 18, 2017 | Press Releases
Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure. The announcement was made on December 12, 2017 by Impulse...
by Impulse Dynamics | Aug 7, 2017 | Press Releases
Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm Continued Access evaluation of the company’s Cardiac...
by Impulse Dynamics | May 11, 2017 | Press Releases
Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round. The equity financing...
by Impulse Dynamics | Mar 3, 2017 | Press Releases
Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are...
